Clinical Trial Update: First Year Impact of Nirsevimab on Paediatric Respiratory Syncytial Virus Infection and Hospitalisations in the Australian Capital Territory

View source ↗

Summary

The study reports on the first-year impact of Nirsevimab on pediatric Respiratory Syncytial Virus infection and related hospitalisations in the Australian Capit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• BEYFORTUS (Nirsevimab)

Snippet

Sponsor: Nicola Irwin | Conditions: Respiratory Syncytial Viral (RSV) Infection, Respiratory Syncytial Virus Hospitalizations | Status: COMPLETED